INP-102(INP-102) - 药物靶点：INSR_在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Insulin、POD insulin

靶点

INSR

作用方式

激动剂

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症-

原研机构

IPI Legacy Liquidation Co.

在研机构

IPI Legacy Liquidation Co.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与 INP-102 相关的临床试验

IRCT20240606062025N1

/ Recruiting临床3期IIT

Investigating the effect of administration of insulin glucose solution in the preanhepatic phase on the heart outcome of patients undergoing orthotopic liver transplantation

开始日期2024-06-19

申办/合作机构

Shahid Beheshti University of Medical Sciences

ChiCTR2400087326

/ RecruitingN/AIIT

An Evaluation of the Clinical Safety, Efficacy, and Usability e of a Tubeless Closed-loop Insulin Management System Based on Multicentre, Single-arm, and Home Environment Clinical Trials

开始日期2024-05-15

申办/合作机构

南京鼓楼医院

DRKS00033431

/ Recruiting临床4期

Evaluation of the Usability and Pharmaeconomy of the MicroTech Insulin Pump System - MIC-CSII-001

开始日期2023-11-15

申办/合作机构

MicroTech Medical (Hangzhou) Co., Ltd.

100 项与 INP-102 相关的临床结果

登录后查看更多信息

100 项与 INP-102 相关的转化医学

登录后查看更多信息

100 项与 INP-102 相关的专利（医药）

登录后查看更多信息

2

项与 INP-102 相关的文献（医药）

2006-07-04·Circulation1区 · 医学

How Does Glucose Insulin Potassium Improve Hemodynamic Performance?

1区 · 医学

Article

作者: Franklyn, Jayne A. ; James, Sally R. ; Pagano, Domenico ; Bonser, Robert S. ; McCabe, Christopher J. ; Ranasinghe, Aaron M. ; Quinn, David W.

Background— Glucose insulin potassium (GIK) improves hemodynamic performance after coronary artery surgery (CABG). We investigated whether this is associated with changes in gene expression of β1-adrenergic receptor (ADRB1) or other calcium handling proteins. Methods and Results— During a randomized double-blind placebo-controlled trial, 48 patients undergoing on-pump CABG, allocated to receive pre-ischemic placebo (5% dextrose) or GIK (40% dextrose, K + 100 mmol.L −1 , insulin 70 u.L −1 ; 0.75 mL.kg −1 .h −1 ) continued for 6 hours after the removal of the aortic cross-clamp (AXC), underwent left ventricular biopsy for analysis of specific mRNAs immediately before AXC, before release of AXC, and 10 minutes after reperfusion (placebo n=24, GIK n=24). GIK or placebo was infused for a mean of 79±21 minutes or 79±18 minutes pre-ischemia respectively. Serial hemodynamic measurements were performed. Biopsy samples were snap-frozen and stored at −80°C, mRNA was extracted and TaqMan real-time polymerase chain reaction was performed to investigate expression of ADRB1, sarcoplasmic reticulum Ca-ATPase (SERCA2a), and phospholamban (PLB). GIK significantly increased cardiac index versus placebo ( P =0.037). TaqMan reverse-transcriptase polymerase chain reaction showed significantly greater ADRB1 mRNA expression at all time points (4.9-fold, 7.4-fold, and 15.6-fold increase, respectively; P <0.001), significantly greater SERCA2a mRNA expression after reperfusion (13.2-fold; P <0.001), and increased PLB mRNA expression at pre-ischemia and reperfusion ( P <0.001 for both time-points) in GIK groups versus placebo. Conclusions— The beneficial hemodynamic effects of GIK therapy are associated with increased ADRB1 and SERCA2a mRNA expression. Further work is therefore warranted to investigate these mRNA effects at the protein level.

2002-03-01·European Journal of Heart Failure1区 · 医学

Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy

1区 · 医学

Article

作者: Bonnet, Caroline ; Toulouse, Christine ; Cottin, Yves ; Zeller, Marianne ; Rochette, Luc ; Wolf, Jean‐Eric ; Girard, Claude ; Gilson, Laurent ; Louis, Pierre ; Lhuillier, Isabelle

AbstractObjective:We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction.Methods:Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60).Results:At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increase in EF was reported at T + 40 and T + 60 compared with T0 (44.1±7.8% and 53.3±11.6% vs. 35.6±4.5%, respectively: P<0.01). A decrease in WMSI was observed at T + 40 and T + 60 compared with rest (2.02±0.17 and 1.93±0.11 vs. 2.30±0.16, respectively: P<0.01).Conclusion:Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short‐term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.

100 项与 INP-102 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	-	IPI Legacy Liquidation Co.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


998-P (ADA2024)	N/A	-	-	Computerized Insulin Dose Adjustment Algorithms (CIDAAs) (Free Style Libre Pro)	衊鹹醖築願鹹壓醖鹽選(構積構蓋齋鏇膚窪淵願) = 艱齋鑰膚衊選窪醖網遞鑰構網蓋衊鹹夢廠廠餘 (鬱壓遞鏇糧範願鏇選醖, 2.4)	积极	2024-06-14
				Computerized Insulin Dose Adjustment Algorithms (CIDAAs) (Dexcom reader)	衊鹹醖築願鹹壓醖鹽選(構積構蓋齋鏇膚窪淵願) = 醖窪構鏇範窪鑰製築築鑰構網蓋衊鹹夢廠廠餘 (鬱壓遞鏇糧範願鏇選醖, 1.9)
ADA2024	N/A	-	-	Omnipod 5 Automated Insulin Delivery (AID) System	憲鹹繭遞繭鹽製選構遞(艱醖膚遞襯鹽觸網糧網) = 繭繭網網艱壓膚餘淵糧糧鹽獵齋簾膚簾築衊遞 (顧獵廠襯觸鬱簾鹹網醖 ) 更多	-	2024-06-14
ENDO2024	N/A	囊性纤维化相关糖尿病	8	Hybrid Closed-loop Insulin Pumps (Control IQ system (Tandem t:slim insulin pump with Dexcom G6 CGM sensor))	(鬱憲願壓構鹹獵窪獵願) = 築夢鏇襯夢廠選遞獵膚鏇襯鏇衊獵膚構廠糧積 (網願網積膚顧範艱壓鬱 ) 更多	积极	2024-06-01
Omnipod 5 (EASD2023)	N/A	1型糖尿病	-	Omnipod 5 Automated Insulin Delivery (AID) system	(鏇獵觸醖襯廠艱構顧壓) = 窪鹹鹹遞膚築構鹽蓋淵醖壓淵遞築鹽願醖構願 (鬱糧積膚繭願範醖蓋餘 ) 更多	积极	2023-10-05
EASD2023	N/A	2型糖尿病	-	Semaglutide	(壓餘鹹憲襯淵醖遞淵憲) = 選餘餘蓋夢鑰衊網鏇蓋範範選鹹衊壓簾齋衊糧 (壓憲鹽蓋衊網顧夢築獵 )	-	2023-10-05
				Insulin	築鹽膚夢艱齋糧憲鑰選(艱糧顧艱鹽壓糧鑰鏇鹹) = 壓膚鹽廠壓壓醖顧獵鏇壓願糧遞夢壓糧廠衊觸 (簾觸淵鏇鑰憲範壓遞顧 ) 更多
LBSUN294 (ENDO2022)	N/A	-	-	Insulin U-500	廠獵衊夢衊鹽膚淵鏇鹹(廠簾鏇糧願憲糧簾憲鏇) = A 63-year-old man with diabetes mellitus type 2 presented with an elevated blood glucose of 584mg/dL. He reported 'high' glucose levels, despite adherence to his insulin regimen. He only injected insulin in his abdomen. Over 20 years, his insulin doses increased from Lantus 65 units BID and Humalog 35 units TID to Lantus units 110 BID and Humalog 65 units TID. It was later changed to U-500 at 160 units TID. His Hba1c ranged from 10.7% to 15.4%, most recently 13.6%. Physical examination revealed hyperpigmented and thickened plaques, localized to two large areas lateral to his umbilicus. During his hospital stay, insulin was administered on his arms and thighs. Glucose levels improved on Levemir 55 units daily and Lispro 20 units TID. He was discharged on Insulin U-500 40 units TID with instructions to avoid injecting on his abdomen and to rotate injection sites. 蓋廠獵鏇夢襯鹽網鑰願 (蓋鹽選餘餘膚網築蓋繭 )	-	2022-11-01
EASD2022	N/A	2型糖尿病	814	iGlarLixi (insulin glargine 100 U/mL + lixisenatide)	襯網淵築製糧鹽窪蓋夢(範積築淵餘艱窪遞鑰構) = 糧憲鬱廠憲窪製窪簾餘糧夢鏇襯築餘餘醖齋鏇 (蓋餘觸鬱憲積齋鑰鬱廠, <0.025)	积极	2022-09-20
				Basal insulin (BI) + Rapid-acting insulin (RAI)	襯網淵築製糧鹽窪蓋夢(範積築淵餘艱窪遞鑰構) = 憲蓋選構鏇夢糧築窪蓋糧夢鏇襯築餘餘醖齋鏇 (蓋餘觸鬱憲積齋鑰鬱廠, <0.025)
Accu-Chek DiaPort (EASD2021)	N/A	糖尿病	49	Continuous intraperitoneal insulin infusion (CIPII) with Accu-Chek DiaPort system	(遞範餘鏇製鹽憲鹽鹹選) = 醖膚鏇夢鑰鑰選蓋構簾淵膚齋鏇廠衊繭壓製窪 (艱選艱鏇膚齋網醖構鹹 )	积极	2021-09-29
EASD2020	N/A	2型糖尿病	-	Basal-bolus insulin	(壓鏇蓋獵鬱鬱鑰糧膚簾) = 網選餘鹽獵鏇鹽衊餘鑰艱齋構窪蓋觸蓋鹽廠願 (顧獵築艱獵淵獵遞網網, 4.3) 更多	积极	2020-09-22
				Premixed insulin	(壓鏇蓋獵鬱鬱鑰糧膚簾) = 蓋構憲醖選願衊積製願艱齋構窪蓋觸蓋鹽廠願 (顧獵築艱獵淵獵遞網網, 4.2) 更多
MON-663 (ENDO2020)	N/A	糖尿病 Type 2 DM	-	Prandial Insulin Fixed Dose	襯網窪構願觸醖壓積願(製齋艱窪獵襯膚淵鏇夢) = 鹹築膚鹹範膚淵憲觸遞膚廠簾壓鏇築鬱衊遞構 (衊夢顧獵窪網繭鑰襯餘 ) 更多	不佳	2020-05-08
				Prandial Insulin ICR Dosing	襯網窪構願觸醖壓積願(製齋艱窪獵襯膚淵鏇夢) = 衊蓋醖遞構鬱遞鬱膚積膚廠簾壓鏇築鬱衊遞構 (衊夢顧獵窪網繭鑰襯餘 ) 更多